EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Seroprevalence Trends of Antibodies to SARS‐CoV‐2 in South Korea, 2021–2022: A Repeated Cross‐Sectional Study

Ah-Ra Kim, Chiara Achangwa, Hyeon Nam Do, Eun Young Jang, Yukyung Nam, Seonghui Cho, Taegu Kim, Hye-Sook Jeong, Gi-Eun Rhie, Kyungwon Oh, Seunghyun Lewis Kwon, Seunghyeon Lee und 2 weitere

Influenza and Other Respiratory Viruses · 2025

DOI: 10.1111/irv.70117 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2025. Verfasst von Ah-Ra Kim und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Research for Vaccine, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Cheo…. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Antibodies, Viral. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea National Institute of Health, National Research Foundation of Korea, Government-wide Research and Development to Advance Infectious Disease Prevention and Control, Republic of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Monitoring immunity levels nationwide and identifying disparities are important to prepare for future pandemics. However, data regarding changes in the seroprevalence of SARS‐CoV‐2 and disparities in consecutive epidemic waves using existing surveillance systems are limited.

Methods

We conducted a cross‐sectional serosurvey using 11,506 residual serum samples collected from the Korean National Health and Nutrition Examination Survey between January 2021 and December 2022. Antibodies to the SARS‐CoV‐2 spike (anti‐S) protein, indicative of vaccination or past infection of SARS‐CoV‐2, and nucleocapsid (anti‐N) protein, indicating infection, were quantified. Then, we applied post‐stratification weighting through the bootstrap resampling based on the age and sex distribution of the South Korean population. We used regression models to identify any disparities in the seropositivity prevalence ratio (PR) across different epidemic waves of SARS‐CoV‐2 and demographics in the population.

Results

We identified that the anti‐S seropositivity gradually increased after the COVID‐19 vaccination rollout, whereas anti‐N seropositivity increased after the SARS‐CoV‐2 Omicron variant was introduced in Korea. Anti‐S seropositivity PR was 0.12–0.76 times lower in individuals < 18 years than in elderly individuals ≥ 65 years during Waves 4–5 (July 2021 to June 2022). Anti‐N seropositivity PR was 1.25–1.83 times higher in individuals less than 64 years than in elderly individuals during Waves 5–7 (January 2022 to December 2022).

Conclusions

Our findings provide insights into the dynamic changes in immunity levels among the Korean population after the COVID‐19 vaccine rollout and the introduction of the Omicron variant. Identifying the disparity in seroprevalence in the study population during the pandemic by using the existing surveillance system provides helpful information to develop future pandemic preparedness plans for the population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2Antibodies, ViralHumansRepublic of KoreaSeroepidemiologic StudiesCross-Sectional StudiesFemaleMaleMiddle AgedAdultAgedYoung AdultAdolescentSpike Glycoprotein, CoronavirusChildChild, PreschoolCOVID-19 VaccinesCoronavirus Nucleocapsid ProteinsInfantAged, 80 and overPhosphoproteins

Stichwörter der Autor:innen

SARS‐CoV‐2antibodycommunity cohortdisparitysero‐surveillancesurveillance

Substanzen

Antibodies, ViralSpike Glycoprotein, CoronavirusCOVID-19 VaccinesCoronavirus Nucleocapsid Proteinsspike protein, SARS-CoV-2nucleocapsid phosphoprotein, SARS-CoV-2Phosphoproteins

Autor:innen und Institutionen

  • Division of Clinical Research for Vaccine, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Cheongju, South Korea.
  • Department of Preventive Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
  • Division of Vaccine Development, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Cheongju, South Korea.
  • Department of Statistics, Korea University, Seoul, South Korea.
  • Center for Vaccine Research, National Institute of Infectious Diseases, Cheongju, South Korea.
  • Division of Health and Nutrition Survey and Analysis, Department of Chronic Diseases Prevention and Control, Korea Disease Control and Prevention Agency, Cheongju, South Korea.

Förderung

  • Korea National Institute of Health
  • National Research Foundation of Korea
  • Government-wide Research and Development to Advance Infectious Disease Prevention and Control, Republic of Korea

Zitieren

APA

Kim, A. R., Achangwa, C., Do, H. N., Jang, E. Y., Nam, Y., Cho, S., Kim, T., Jeong, H. S., Rhie, G. E., Oh, K., Kwon, S. L., Lee, S., Lee, J., & Ryu, S. (2025). Seroprevalence Trends of Antibodies to SARS‐CoV‐2 in South Korea, 2021–2022: A Repeated Cross‐Sectional Study. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.70117

Vancouver

Kim AR, Achangwa C, Do HN, Jang EY, Nam Y, Cho S, et al. Seroprevalence Trends of Antibodies to SARS‐CoV‐2 in South Korea, 2021–2022: A Repeated Cross‐Sectional Study. Influenza and Other Respiratory Viruses. 2025. doi:10.1111/irv.70117

BibTeX
@article{Kim2025,
  author = {Kim, Ah-Ra and Achangwa, Chiara and Do, Hyeon Nam and Jang, Eun Young and Nam, Yukyung and Cho, Seonghui and Kim, Taegu and Jeong, Hye-Sook and Rhie, Gi-Eun and Oh, Kyungwon and Kwon, Seunghyun Lewis and Lee, Seunghyeon and Lee, Junewoo and Ryu, Sukhyun},
  title = {Seroprevalence Trends of Antibodies to SARS‐CoV‐2 in South Korea, 2021–2022: A Repeated Cross‐Sectional Study},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2025},
  doi = {10.1111/irv.70117}
}
Kostenlos starten →